Clinical trials: Clostridia Difficile Colitis
Moderate Clostridium Difficile Infection
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
- Trial name
- NCT01232595
- Testing
- LFF571, Vancomycin (POC)
- Where
- 18 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Clostridium Enterocolitis, Pseudomembranous Colitis
Response of Clostridium Difficile Infection to Metronidazole Therapy
In this record review study, our objective is to determine the rates of cure, failure and relapse following treatment of C. difficile colitis with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304369
- Testing
- Metronidazole
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut bacteria and is the most effective treatment for patients who suffer from recurrent Clostridioides difficile infection (CDI) brought on by…
- Trial name
- NCT03806803
- Testing
- Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate
- Where
- 5 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Clostridium Difficile, Clostridium Difficile Infection
FQ Restriction for the Prevention of CDI
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs).
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
- Trial name
- FIRST (NCT03848689)
- Testing
- fluoroquinolone preprescription authorization, Control
- Where
- 7 sites in United States
- Volunteers
- 5,871 people
- Sponsor
- University of Wisconsin, Madison
Inflammatory Bowel Diseases, Ulcerative Colitis
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
- Trial name
- NCT04626947
- Testing
- Bezlotoxumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- David Binion, MD
Antibiotic-Associated Diarrhea, Clostridium Difficile
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
To determine whether symptomatic treatment of the diarrhea in CDAD reduces morbidity and mortality of this serious nosocomial infection in patients who have antibiotic-associated diarrhea. Both C.
- Trial name
- loperamide (NCT00591357)
- Testing
- loperamide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Infection
Pathogenic Mechanisms in C Diff Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut.
- Trial name
- NCT01930032
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Clostridioides Difficile Infection
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C.
- Trial name
- PREVENT (NCT06884748)
- Testing
- Ursodiol 500 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile
Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis
Clostridium difficile has become one of the leading causes of hospital acquired infections, and is associated with increased mortality. Patients with C.
- Trial name
- NCT01959048
- Testing
- fecal microbiota transplantation
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Clostridium Difficile, Colitis
The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers
The investigators hypothesize that development of symptoms characteristic of Clostridium difficile infection will be 2-3 times higher in asymptomatic carriers, compared to that of non carriers and expect to find risk factors for…
- Trial name
- NCT02063282
- Where
- Israel
- Volunteers
- 394 people
- Sponsor
- Amos Yinnon
Diarrhea Infectious
Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients
Clostridioides difficile (C. difficile) colitis is a common hospital-acquired disease, which increases hospitalization length and the mortality rate. Moreover, refractory or recurrent C. difficile colitis is an emerging disease.
- Trial name
- CDAD (NCT05770726)
- Testing
- Probiotics administration
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Cheng-Kung University Hospital
Clostridium Difficile Infection, Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
This is a prospective, multicenter, open-label Phase 3 study of a microbiota suspension of intestinal microbes. Patients who have had at least one recurrence of CDI after a primary episode and have completed at least one round of…
- Conditions
- Clostridium Difficile Infection, Infection, Communicable Diseases
- Trial name
- CD3-OLS (NCT03931941)
- Testing
- RBX2660
- Where
- 51 sites in United States, Canada
- Volunteers
- 793 people
- Sponsor
- Rebiotix Inc.
Gastroenteritis, Infectious Colitis
A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients
The ARIES C. difficile Assay is a real-time PCR based qualitative in vitro diagnostic test for the direct detection of C. difficile nucleic acid in stool specimens.
- Trial name
- NCT02497417
- Where
- 4 sites in United States
- Volunteers
- 1,021 people
- Sponsor
- Luminex Corporation
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
study is to determine if proton pump inhibitors plus enteral nutrition is superior to enteral nutrition alone as a stress ulcer prophylaxis strategy in critically ill patients in terms of incidence of overt and significant GI…
- Trial name
- NCT01477320
- Testing
- Pantoprazole 40 mg IV daily and tube feed.
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Mohamed Saad
Clostridium Difficile, Clostridium Difficile Infection
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
The host gastrointestinal microbiota is significantly influenced by antibiotic treatment which might favor Clostridium difficile infection (CDI), a frequent cause of community- and hospital-acquired, potentially life-threatening…
- Trial name
- TOCSIN (NCT01942447)
- Testing
- FMT, Vancomycin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Clostridium Enterocolitis, Pseudomembranous Colitis
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
The purpose of this study is three fold: 1)To collect serum from patients with documented Clostridium difficile infection and test for the presence of antibody to C.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304408
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Enterocolitis, Pseudomembranous, Diarrhea
A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea
Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C.
- Conditions
- Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
- Trial name
- NCT00466635
- Testing
- GT267-004 (tolevamer potassium sodium)
- Where
- 13 sites in United States
- Volunteers
- 65 people
- Sponsor
- Genzyme, a Sanofi Company
Clostridium Difficile Infection-associated Diarrhea and Colitis
Efficacy and Safety of Teicoplanin in CDAD
Primary Objective: Explore the efficacy of teicoplanin (100-200 mg administered orally twice a day for 7 to 14 days) in patients with Clostridium difficile infection-associated diarrhea and colitis Secondary Objective: Evaluate…
- Trial name
- NCT04003818
- Testing
- TEICOPLANIN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sanofi